Urogenital System (e.g., Kidney, Etc.) Patents (Class 424/558)
-
Patent number: 7485855Abstract: A system and method for cleanup of biological samples from contaminants prior to spectroscopy analysis. The system includes a support configured to hold a sample including a liquid having at least one group of biological molecules with a surface of the support binding the molecules at a surface tension angle to the liquid of less than 180 degrees. The system includes an evaporator configured to evaporate liquid from the support, a solvent applicator configured to apply a solvent for dissolution of the contaminants in the sample, and a solvent removal device configured to remove applied solvent from the sample and thereby at least partially remove the contaminants.Type: GrantFiled: May 26, 2006Date of Patent: February 3, 2009Assignee: Science and Engineering Services, Inc.Inventors: Appavu K. Sundaram, Nelli I. Taranenko, Vladimir M. Doroshenko
-
Publication number: 20080260831Abstract: Provided are methods for preparing gelled, solubilized extracellular matrix (ECM) compositions useful as cell growth scaffolds. Also provided are compositions prepared according to the methods as well as uses for the compositions. In one embodiment a device, such as a prosthesis, is provided which comprises an inorganic matrix into which the gelled, solubilized ECM is dispersed to facilitate in-growth of cells into the ECM and thus adaptation and/or attachment of the device to a patient.Type: ApplicationFiled: February 29, 2008Publication date: October 23, 2008Inventors: Stephen F. Badylak, Donald O. Freytes
-
Publication number: 20080254139Abstract: The invention is a method of treating ovarian cancer by contacting a post-surgical site of an ovarian cancer patient with a composition or a sheet article comprising extracellular matrix to inhibit cancer cell attachment, promote wound healing after the surgery, reduce scar formation at the surgical site, regenerate lost tissue, and prevent tumor recurrence at the site or in the peritoneum generally.Type: ApplicationFiled: October 27, 2007Publication date: October 16, 2008Inventor: LEIGH H. FIRESTONE
-
Publication number: 20080193554Abstract: The invention relates to methods of processing amniotic membrane to generate a substantially ‘growth factor free’ membrane (GFF-membrane), and to methods of processing GFF-membrane to generate membrane enriched with specific and quantified levels of growth factors or other desirable membrane enriching molecules or compounds (E-membrane). The invention extends to GFF-membrane per se and E-membrane enriched with specific and quantified membrane-enriching compounds per se. The method also includes first and second medical uses of GFF-membrane and E-membrane. The method also extends to clinical uses of the amniotic membrane spongy layer or components thereof.Type: ApplicationFiled: July 17, 2006Publication date: August 14, 2008Applicant: THE UNIVERSITY OF NOTTINGHAMInventors: Harminder Dua, Andrew Hopkinson
-
Patent number: 7235262Abstract: The invention relates to a novel pharmaceutical composition comprising an effective amount of bio-active fraction from cow urine distillate as a bioavailability facilitator and pharmaceutically acceptable additives selected from anticancer compounds, antibiotics, drugs, therapeutic and nutraceutic agents, ions and similar molecules which are targeted to the living systems.Type: GrantFiled: April 13, 2004Date of Patent: June 26, 2007Assignee: Council of Scientific and Industrial ResearchInventors: Suman Preet Singh Khanuja, Sushil Kumar, Ajit Kumar Shasany, Jai Shankar Arya, Mahendra Pandurang Darokar, Monika Singh, Prachi Sinha, Soumya Awasthi, Subhash Chandra Gupta, Vivek Kumar Gupta, Madan Mohan Gupta, Ram Kishore Verma, Sweta Agarwal, Sunil Balkrishna Mansinghka, Suresh Haribhau Dawle
-
Patent number: 6896907Abstract: The invention relates to a novel pharmaceutical composition comprising an effective amount of bio-active fraction from cow urine distillate as a bioavailability facilitator and pharmaceutically acceptable additives selected from anticancer compounds, antibiotics, drugs, therapeutic and nutraceutic agents, ions and similar molecules which are targeted to the living systems.Type: GrantFiled: May 1, 2002Date of Patent: May 24, 2005Assignee: Council of Scientific and Industrial ResearchInventors: Suman Preet Singh Khanuja, Sushil Kumar, Ajit Kumar Shasany, Jai Shankar Arya, Mahendra Pandurang Darokar, Monika Singh, Prachi Sinha, Soumya Awasthi, Subhash Chandra Gupta, Vivek Kumar Gupta, Madan Mohan Gupta, Ram Kishore Verma, Sweta Agarwal, Sunil Balkrishna Mansinghka, Suresh Haribhau Dawle
-
Patent number: 6890564Abstract: A matrix, including epithelial basement membrane, for inducing repair of mammalian tissue defects and in vitro cell propagation derived from epithelial tissues of a warm-blooded vertebrate.Type: GrantFiled: October 25, 2002Date of Patent: May 10, 2005Assignee: ACell, Inc.Inventor: Alan R. Spievack
-
Patent number: 6887495Abstract: A matrix, including epithelial basement membrane, for inducing repair of mammalian tissue defects and in vitro cell propagation derived from epithelial tissues of a warm-blooded vertebrate.Type: GrantFiled: October 25, 2002Date of Patent: May 3, 2005Assignee: ACell, Inc.Inventor: Alan R. Spievack
-
Patent number: 6861074Abstract: A matrix, including epithelial basement membrane, for inducing repair of mammalian tissue defects and in vitro cell propagation derived from epithelial tissues of a warm-blooded vertebrate.Type: GrantFiled: October 25, 2002Date of Patent: March 1, 2005Assignee: ACell, Inc.Inventor: Alan R. Spievack
-
Patent number: 6849273Abstract: A matrix, including epithelial basement membrane, for inducing repair of mammalian tissue defects and in vitro cell propagation derived from epithelial tissues of a warm-blooded vertebrate.Type: GrantFiled: October 25, 2002Date of Patent: February 1, 2005Assignee: ACell, Inc.Inventor: Alan R. Spievack
-
Patent number: 6783776Abstract: A matrix, including epithelial basement membrane, for inducing repair of mammalian tissue defects and in vitro cell propagation derived from epithelial tissues of a warm-blooded vertebrate.Type: GrantFiled: October 25, 2002Date of Patent: August 31, 2004Assignee: ACell, Inc.Inventor: Alan R. Spievack
-
Publication number: 20040109899Abstract: There is disclosed a prophylactic and therapeutic antiviral composition and in particular compositions which comprise containing vertebrates kidney as a main component. Use of the composition through parenteral administration for the prevention and treatment of viral-induced tumors, lesions and diseases in mammals such as humans or to prepare a medicament is also disclosed. The composition is very effective in preventing and treating viral infections and manifestations as hyperplasia, keratosis, and dermatosis and in particular those caused by Papillomavirus and more particularly Human Papillomavirus. Among the many benefits, the present compounds provide high remedial effect and complete resolution in a relatively short course of treatment with no risk of side effects what so ever. The composition is abundant, inexpensive, easily prepared, and may be self administered to the afflicted area by the patients themselves.Type: ApplicationFiled: December 8, 2002Publication date: June 10, 2004Inventor: Tareq Abduljalil Albahri
-
Patent number: 6649160Abstract: A method of producing a sustained localized immunosuppressive effect in localized tissues is achieved by transplanting Sertoli cells proximate to the tissue.Type: GrantFiled: September 14, 2000Date of Patent: November 18, 2003Assignee: University of South FloridaInventors: Paul R. Sanberg, Don F. Cameron, Cesario V. Borlongan
-
Patent number: 6579538Abstract: A matrix, including epithelial basement membrane, for inducing repair of mammalian tissue defects and in vitro cell propagation derived from epithelial tissues of a warm-blooded vertebrate.Type: GrantFiled: October 18, 2000Date of Patent: June 17, 2003Assignee: ACell, Inc.Inventor: Alan R. Spievack
-
Publication number: 20030096016Abstract: A method of treating a kidney disease in a subject is disclosed. The method is effected by transplanting into the subject a graft of nephric tissue at a predetermined developmental stage thereby treating the kidney disease in the subject.Type: ApplicationFiled: April 10, 2002Publication date: May 22, 2003Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.Inventors: Yair Reisner, Benjamin Dekel
-
Publication number: 20030060787Abstract: A kidney stone collection device includes entrance and settling chambers coupled at a junction, an inlet opening into the entrance chamber, and an outlet conduit including the device outlet. The outlet conduit also has outlet conduit entrance which opens into the settling chamber. The device includes a base defining the bottom of the settling chamber when the body is in an upright orientation. The outlet conduit entrance is at a higher elevation than at least a portion of the base when the body is in the upright orientation. The body may be made of a pliable and/or transparent material so that the user may see and/or feel kidney stones collected at the base. A shape-maintaining frame element may be used at the inlet to permit the inlet to be maintained in an open configuration.Type: ApplicationFiled: August 13, 2002Publication date: March 27, 2003Inventors: Cu Ngoc Phan, Khiem Thanh Tran
-
Publication number: 20030026846Abstract: A method of using peracid/acid compositions, where the mole ratio of acid to peracid is less than about 3:1, to treat field or greenhouse grown plant tissue, seeds, fruits, and growing media and containers is described. The peracid/acid system can lower the natural, plant pathogen and human pathogenic microbial load resulting in less waste to molding, spoilage, and destruction because of pathogenic poisons.Type: ApplicationFiled: June 29, 2001Publication date: February 6, 2003Applicant: Ecolab Inc.Inventors: Robert D.P. Hei, John Dennis Hilgren, Joy Ann Salverda, Brandon Leon Herdt
-
Patent number: 6485723Abstract: An improved tissue graft construct comprising submucosa of a warm-blooded vertebrate and a preselected group of eukaryotic cells are described. The improved tissue graft constructs can be used in accordance with the present invention to enhance the repair of damaged or diseased tissues in vivo.Type: GrantFiled: May 8, 2000Date of Patent: November 26, 2002Assignee: Purdue Research FoundationInventors: Stephen F. Badylak, Christina Lindberg, George B. Boder, Sherry Voytik-Harbin
-
Patent number: 6410059Abstract: A pharmaceutical composition comprising an antibiotic and cow urine distillate in an amount effective to enhance antimicrobial effect of the antibiotic is disclosed. The antibiotic can be an antifungal agent. The antibiotic can be a quinolone or a fluoroquinolone. The antifungal agent can be azoles, clotrimazole, mystatin or amphotericin.Type: GrantFiled: December 1, 2000Date of Patent: June 25, 2002Assignee: Council of Scientific and Industrial ResearchInventors: Suman Preet Singh Khanuja, Sushil Kumar, Ajit Kumar Shasany, Jai Shankar Arya, Mahendra Pandurang Darokar, Monika Singh, Prachi Sinha, Soumya Awasthi, Subhash Chandra Gupta, Vivek Kumar Gupta, Madan Mohan Gupta, Ram Kishore Verma, Sweta Agarwal, Sunil Balkrishna Mansinghka, Suresh Haribhau Dawle
-
Publication number: 20020039599Abstract: Disclosed is a method of treating small intestinal bacterial overgrowth (SIBO) or a SIBO-caused condition in a human subject. SIBO-caused conditions include irritable bowel syndrome, fibromyalgia, chronic pelvic pain syndrome, chronic fatigue syndrome, depression, impaired mentation, impaired memory, halitosis, tinnitus, sugar craving, autism, attention deficit/hyperactivity disorder, drug sensitivity, an autoimmune disease, and Crohn's disease. Also disclosed are a method of screening for the abnormally likely presence of SIBO in a human subject and a method of detecting SIBO in a human subject. A method of determining the relative severity of SIBO or a SIBO-caused condition in a human subject, in whom small intestinal bacterial overgrowth (SIBO) has been detected, is also disclosed.Type: ApplicationFiled: April 17, 2001Publication date: April 4, 2002Inventors: Henry C. Lin, Mark Pimentel
-
Publication number: 20010048949Abstract: Methods and materials for tissue reconstruction, repair, and/or augmentation are disclosed. The invention provides isolated bladder submucosa for use in tissue reconstruction. The methods of the invention include the use of isolated bladder submucosa for repair, reconstruction, and/or augmentation of bladder and other organs and tissues.Type: ApplicationFiled: August 15, 1997Publication date: December 6, 2001Applicant: Children's Medical Center CorporationInventor: ANTHONY ATALA
-
Patent number: 6054142Abstract: A biocompatible cell device having an internal foam scaffold to provide a growth surface for encapsulated cells which produce a biologically active molecule.Type: GrantFiled: August 1, 1996Date of Patent: April 25, 2000Assignee: Cyto Therapeutics, Inc.Inventors: Rebecca Li, Tyrone F. Hazlett
-
Patent number: 5928670Abstract: An intrinsic aldose reductase inhibitor is isolated and purified from mammalian cells, such as rat or human kidney cells. The intrinsic aldose reductase inhibitor may be incorporated into pharmaceutical compositions for the treatment of certain conditions related to diabetes.Type: GrantFiled: November 26, 1997Date of Patent: July 27, 1999Assignee: The Government of the United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Peter F. Kador, Yukio Takahashi, Tomoyuki Terada, Libaniel Rodriguez, Matteo Schaffhauser
-
Patent number: 5824493Abstract: A method of diagnosing interstitial cystitits in an individual and a kit for the method, comprising the steps of: obtaining primary cultures of urothelial cells; selecting urothelial cells of basal type and producing secondary cultures; measuring in secondary cultures (1) percentage of single cells and percentage of large colonies; (2) determining proliferative ability; (3) determining differentiation ability; (4) determining the percentage of large colonies that express phosphotyrosine and/or nitrotyrosine; (5) measuring the percentage of apoptotic cells; (6) measuring the percentage of large colonies; and (7) comparing the percentage of the colonies to baseline values of the same parameters determined in samples of similarly cultured urothelial cells taken from individuals not suspected of having interstitial cystitis.Type: GrantFiled: February 23, 1996Date of Patent: October 20, 1998Assignee: University of Alabama Research FoundationInventor: Ada Elgavish
-
Patent number: 5738878Abstract: An intrinsic aldose reductase inhibitor is isolated and purified from mammalian cells, such as rat or human kidney cells. The intrinsic aldose reductase inhibitor may be incorporated into pharmaceutical compositions for the treatment of certain conditions related to diabetes.Type: GrantFiled: June 5, 1995Date of Patent: April 14, 1998Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Peter F. Kador, Yukio Takahashi, Tomoyuki Terada, Libaniel Rodriguez, Matteo Schaffhauser
-
Patent number: 5702700Abstract: A method of generating in situ trophic factor production by transplanting Sertoli cells into the central nervous system of a mammal, the cells creating trophic factors in situ.Type: GrantFiled: March 13, 1995Date of Patent: December 30, 1997Assignee: University of South FloridaInventors: Paul R. Sanberg, Don F. Cameron, Cesario V. Borlongan
-
Patent number: 5700783Abstract: A method for treating urinary incontinence consisting of injecting human fibrin glue at or near the bladder neck until the urethral outflow resistance is restored. Human fibrin glue is the reaction product of human fibrinogen and thrombin in the presence of calcium chloride as catalyst.Type: GrantFiled: April 24, 1995Date of Patent: December 23, 1997Assignee: Angelo PintoInventor: Angelo Pinto
-
Patent number: 5695785Abstract: The invention is directed to a method of treating systematic lupus erythematosus (SLE) in animals, including humans, by the oral administration of kidney extracts to decrease anti-DNA antibody production. The method of the invention includes both prophylactic and therapeutic measures.Type: GrantFiled: June 27, 1996Date of Patent: December 9, 1997Assignee: Masonic Medical Research LaboratoryInventor: William Ofosu-Appiah
-
Patent number: 5560936Abstract: An intrinsic aldose reductase inhibitor is isolated and purified from mammalian cells, such as rat or human kidney cells. The intrinsic aldose reductase inhibitor may be incorporated into pharmaceutical compositions for the treatment of certain conditions related to diabetes.Type: GrantFiled: October 26, 1993Date of Patent: October 1, 1996Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Peter F. Kador, Yukio Takahashi, Tomoyuki Terada, Libaniel Rodriguez, Matteo Schaffhauser
-
Patent number: 5560935Abstract: The present invention provides a physiologically active substance which inhibits plasma kallikrein production, improves peripheral blood flow, and exhibits analgesic, antiinflammatory and antiallergic action. The physiologically active substance of the present invention is prepared by activating various animals or animal tissues by means of inoculation with virus or tumor cells which act as a stressor, and then extracting the effective factor from the activated tissues. The substance exhibits a pharmacological action of inhibiting activity for production of plasma kallikrein and recovering and normalizing abnormal functions which are associated with the diseased state. The physiologically active substance and pharmaceutical compositions of the present invention exhibit excellent regulating activity for biofunctions. They provide recovery and normalization of abnormal functions in living organisms in various diseased states.Type: GrantFiled: September 27, 1994Date of Patent: October 1, 1996Assignee: Nippon Zoki Pharmaceutical Co., Ltd.Inventors: Jin-emon Konishi, Giichi Hamada
-
Patent number: 5554389Abstract: A tissue graft composition comprising bladder submucosal tissue delaminated from abluminal muscle layers and at least the luminal portion of the tunica mucosa of a segment of vertebrate urinary bladder is described. The graft composition can be implanted to replace or support damaged or diseased tissues.Type: GrantFiled: April 7, 1995Date of Patent: September 10, 1996Assignee: Purdue Research FoundationInventors: Stephen F. Badylak, Sherry L. Voytik, Andrew Brightman, Matt Waninger
-
Patent number: 5510263Abstract: A method for growing endocrine precursor cells in vitro, such as pancreatic islet precursors, by culturing such cells in the presence or absence of cell matrix proteins capable of promoting hemidesmosome formation, such as those produced by the rat bladder carcinoma cell line 804G.Type: GrantFiled: November 12, 1993Date of Patent: April 23, 1996Assignee: Desmos, Inc.Inventors: Vito Quaranta, Jonathan C. R. Jones
-
Patent number: 5476922Abstract: Autocrine growth factors and isoforms of those factors have been identified, isolated, purified and manipulated. Nucleic acid segments coding for the factors, and antibodies directed to the factors are also aspects of the present invention. The effect of these growth factors on cells is to enhance their growth by increasing mitogenesis. In particular, the growth factors stimulate kidney epithelial cell growth. The growth factors differ from others previously reported in their molecular weights and other properties, for example, resistance to denaturation by dithiothreitol. Methods of preparation and use of the factors are also described. The growth factors are released from kidney epithelial cells by short exposures to a low-sodium environment. The factors have potential for treatment of kidney disease.Type: GrantFiled: September 22, 1993Date of Patent: December 19, 1995Assignee: ARCH Development CorporationInventors: F. Gary Toback, Margaret Walsh-Reitz, Stephen L. Gluck
-
Patent number: 5324822Abstract: A method of isolation of a material with similar immunological properties to CA-195 from human amniotic fluid has been disclosed. This material can be substituted for CA-195 in many processes, for example in the preparation of analytical control materials.Type: GrantFiled: December 21, 1992Date of Patent: June 28, 1994Assignee: Ciba Corning Diagnostics Corp.Inventor: Thomas H. Duffy
-
Patent number: 5268175Abstract: Topical cosmetic and pharmaceutical compositions are provided for the external protection of human or animal tissues from contact with heavy metals, and the composition includes a metal sequestering component capable of binding metal ions and a physiologically inert carrier suitable for topical administration. The metal sequestering component one or more metal binding peptide having a high proportion of cysteine residues, for example a metallothionein.Type: GrantFiled: March 24, 1992Date of Patent: December 7, 1993Assignee: Indena SpAInventors: Ezio Bombardelli, Cesare Ponzone, Pier P. Puglisi
-
Patent number: 5198216Abstract: A composition for enhancing the performance of animals, such as horses or dogs, is composed of adrenal and pituitary raw tissue concentrates, vitamin C, bioflavonoid complex, pantothenic acid, methionine, choline, vitamin B1, vitamin B2, vitamin B6, niacinamide, magnesium, vitamin B12, folic acid and organic iodine. The composition is adapted to be orally administered to an animal, is composed of all natural substances, and the relative proportions of the components are approximately:at least 40 parts adrenal raw tissue concentrate toat least 2 parts pituitary raw tissue concentrate to30-60 parts vitamin C to20-30 parts magnesium to10-20 parts of each of pantothenic acid, methionine and choline to8-15 parts of each of niacinamide and bioflavonoid complex to1-5 parts of each of vitamins B1, B2 and B6 to0.1-1 parts organic iodine to0.05-0.5 parts folic acid.Type: GrantFiled: July 30, 1990Date of Patent: March 30, 1993Assignee: Daliff CorporationInventor: David M. McGee
-
Patent number: 5057324Abstract: A physiologically active substance is extracted from infected tissues inoculated with a poxvirus. The novel substance of the present invention has inhibitory action against the formation of kallikrein, thus is useful as drugs such as antiinflammatory, analgesic and antiallergic agents.Type: GrantFiled: July 20, 1988Date of Patent: October 15, 1991Assignee: Nippon Zoki Pharmaceutical Co., Ltd.Inventors: Yoji Shibayama, Yoshio Toyomaki
-
Patent number: 4985254Abstract: The present invention relates to physiologically active substances extracted from infected tissues inoculated with a poxvirus. The substances of the present invention have excellent actions to improve blood flow and recover functions of diseased tissues, thus are useful as drugs for various diseases caused by blood flow disorders.Type: GrantFiled: November 3, 1988Date of Patent: January 15, 1991Assignee: Nippon Zoki Pharmaceutical Co., Ltd.Inventor: Jin-emon Konishi
-
Patent number: 4985542Abstract: Purified glomerular proteoglycans are used as a basis for a diagnostic test for glomerulonephritis in humans involving an immunological reaction between the purified proteoglycans and patient area. A new method for purification of glomeruli proteoglycan antigens is described using guanidine extraction.Type: GrantFiled: May 17, 1989Date of Patent: January 15, 1991Assignee: The Rockefeller UniversityInventors: Howard Fillit, Shridhar P. Damle, John Zabriskie, John D. Gregory
-
Patent number: 4963358Abstract: An agent for inhibiting proliferation of human malignant tumor cells is obtained by culturing the human malignant tumor cells in a medium and removing the malignant tumor cells from the cultured medium.Type: GrantFiled: December 9, 1988Date of Patent: October 16, 1990Assignees: Koken Ltd., Tadakatsu Oishi, Youichiro Nagasu, Hisao YamaguchiInventor: Tomoyuki Tajima